A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)

NCT06708949 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma, Clear Cell

Interventions

DRUG: Drugs Nivolumab
DRUG: Ipilimumab
DRUG: BMS-986213 (Relatlimab-Nivolumab FDC)

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]